Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production

Cindy Tung, Howard J. Federoff, Michael Brownlee, Howard Karpoff, Tracey Weigel, Murray F. Brennan, Yuman Fong

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Production of autologous tumor vaccines would be facilitated by the development of a rapid and efficient method for the transfer of genes into freshly isolated cells. To evaluate the potential of replication defective herpes simplex viral (HSV) amplicon vectors as gene transfer vehicles for tumor vaccine generation, a vector that expresses the human interleukin-2 (IL-2) gene (HSV-IL2) and one that expresses Escherichia coli β-galactosidase (HSVlac) were tested in hepatoma cells of both murine and human origin, gene transfer into murine hepatoma cells (HEPA 1-6) was both rapid and highly efficient: greater than 50% of cells expressed P-Gal when infected at a multiplicity of infection (m.o.i.) of 1 with an exposure period of 20 min. Moreover, gene transfer was as efficient in tumor cells after irradiation with 10,000 rads as in nonirradiated tumor cells. Irradiated HEPA 1-6 cells infected with HSV-IL2 for 20 min secreted IL-2 at a rate of 1,200 ± 160 ng/106 cells per day. C57B1/6J mice immunized with irradiated, HSV-IL-2-transduced tumor cells produced in this way demonstrated specific tumor immunity by in vitro splenocyte tumoricidal activity and by in vivo protection against tumor challenge. Human hepatobiliary tumor specimens harvested at the time of operation, irradiated, and infected with HSV-IL-2 also produced nanogram quantities of IL-2/106 cells per 24 hr. These results indicate that the HSV amplicon vector is a good candidate vehicle for gene transfer in the production of autologous tumor vaccines. By allowing rapid gene transfer to freshly harvested tumor specimens, these vectors bypass the requirement for cell culture and make feasible reinfusion of genetically modified and irradiated autologous cells within hours of tumor harvest.

Original languageEnglish (US)
Pages (from-to)2217-2224
Number of pages8
JournalHuman Gene Therapy
Volume7
Issue number18
StatePublished - Dec 1 1996

Fingerprint

Simplexvirus
Interleukin-2
Vaccines
Herpes Simplex
Genes
Neoplasms
Cancer Vaccines
Hepatocellular Carcinoma
Galactosidases
Immunity
Cell Culture Techniques
Escherichia coli

ASJC Scopus subject areas

  • Genetics

Cite this

Tung, C., Federoff, H. J., Brownlee, M., Karpoff, H., Weigel, T., Brennan, M. F., & Fong, Y. (1996). Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production. Human Gene Therapy, 7(18), 2217-2224.

Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer : Implications for autologous vaccine production. / Tung, Cindy; Federoff, Howard J.; Brownlee, Michael; Karpoff, Howard; Weigel, Tracey; Brennan, Murray F.; Fong, Yuman.

In: Human Gene Therapy, Vol. 7, No. 18, 01.12.1996, p. 2217-2224.

Research output: Contribution to journalArticle

Tung, C, Federoff, HJ, Brownlee, M, Karpoff, H, Weigel, T, Brennan, MF & Fong, Y 1996, 'Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production', Human Gene Therapy, vol. 7, no. 18, pp. 2217-2224.
Tung, Cindy ; Federoff, Howard J. ; Brownlee, Michael ; Karpoff, Howard ; Weigel, Tracey ; Brennan, Murray F. ; Fong, Yuman. / Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer : Implications for autologous vaccine production. In: Human Gene Therapy. 1996 ; Vol. 7, No. 18. pp. 2217-2224.
@article{d7730c85b8ca407ea7af5bb7c702123a,
title = "Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production",
abstract = "Production of autologous tumor vaccines would be facilitated by the development of a rapid and efficient method for the transfer of genes into freshly isolated cells. To evaluate the potential of replication defective herpes simplex viral (HSV) amplicon vectors as gene transfer vehicles for tumor vaccine generation, a vector that expresses the human interleukin-2 (IL-2) gene (HSV-IL2) and one that expresses Escherichia coli β-galactosidase (HSVlac) were tested in hepatoma cells of both murine and human origin, gene transfer into murine hepatoma cells (HEPA 1-6) was both rapid and highly efficient: greater than 50{\%} of cells expressed P-Gal when infected at a multiplicity of infection (m.o.i.) of 1 with an exposure period of 20 min. Moreover, gene transfer was as efficient in tumor cells after irradiation with 10,000 rads as in nonirradiated tumor cells. Irradiated HEPA 1-6 cells infected with HSV-IL2 for 20 min secreted IL-2 at a rate of 1,200 ± 160 ng/106 cells per day. C57B1/6J mice immunized with irradiated, HSV-IL-2-transduced tumor cells produced in this way demonstrated specific tumor immunity by in vitro splenocyte tumoricidal activity and by in vivo protection against tumor challenge. Human hepatobiliary tumor specimens harvested at the time of operation, irradiated, and infected with HSV-IL-2 also produced nanogram quantities of IL-2/106 cells per 24 hr. These results indicate that the HSV amplicon vector is a good candidate vehicle for gene transfer in the production of autologous tumor vaccines. By allowing rapid gene transfer to freshly harvested tumor specimens, these vectors bypass the requirement for cell culture and make feasible reinfusion of genetically modified and irradiated autologous cells within hours of tumor harvest.",
author = "Cindy Tung and Federoff, {Howard J.} and Michael Brownlee and Howard Karpoff and Tracey Weigel and Brennan, {Murray F.} and Yuman Fong",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "7",
pages = "2217--2224",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "18",

}

TY - JOUR

T1 - Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer

T2 - Implications for autologous vaccine production

AU - Tung, Cindy

AU - Federoff, Howard J.

AU - Brownlee, Michael

AU - Karpoff, Howard

AU - Weigel, Tracey

AU - Brennan, Murray F.

AU - Fong, Yuman

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Production of autologous tumor vaccines would be facilitated by the development of a rapid and efficient method for the transfer of genes into freshly isolated cells. To evaluate the potential of replication defective herpes simplex viral (HSV) amplicon vectors as gene transfer vehicles for tumor vaccine generation, a vector that expresses the human interleukin-2 (IL-2) gene (HSV-IL2) and one that expresses Escherichia coli β-galactosidase (HSVlac) were tested in hepatoma cells of both murine and human origin, gene transfer into murine hepatoma cells (HEPA 1-6) was both rapid and highly efficient: greater than 50% of cells expressed P-Gal when infected at a multiplicity of infection (m.o.i.) of 1 with an exposure period of 20 min. Moreover, gene transfer was as efficient in tumor cells after irradiation with 10,000 rads as in nonirradiated tumor cells. Irradiated HEPA 1-6 cells infected with HSV-IL2 for 20 min secreted IL-2 at a rate of 1,200 ± 160 ng/106 cells per day. C57B1/6J mice immunized with irradiated, HSV-IL-2-transduced tumor cells produced in this way demonstrated specific tumor immunity by in vitro splenocyte tumoricidal activity and by in vivo protection against tumor challenge. Human hepatobiliary tumor specimens harvested at the time of operation, irradiated, and infected with HSV-IL-2 also produced nanogram quantities of IL-2/106 cells per 24 hr. These results indicate that the HSV amplicon vector is a good candidate vehicle for gene transfer in the production of autologous tumor vaccines. By allowing rapid gene transfer to freshly harvested tumor specimens, these vectors bypass the requirement for cell culture and make feasible reinfusion of genetically modified and irradiated autologous cells within hours of tumor harvest.

AB - Production of autologous tumor vaccines would be facilitated by the development of a rapid and efficient method for the transfer of genes into freshly isolated cells. To evaluate the potential of replication defective herpes simplex viral (HSV) amplicon vectors as gene transfer vehicles for tumor vaccine generation, a vector that expresses the human interleukin-2 (IL-2) gene (HSV-IL2) and one that expresses Escherichia coli β-galactosidase (HSVlac) were tested in hepatoma cells of both murine and human origin, gene transfer into murine hepatoma cells (HEPA 1-6) was both rapid and highly efficient: greater than 50% of cells expressed P-Gal when infected at a multiplicity of infection (m.o.i.) of 1 with an exposure period of 20 min. Moreover, gene transfer was as efficient in tumor cells after irradiation with 10,000 rads as in nonirradiated tumor cells. Irradiated HEPA 1-6 cells infected with HSV-IL2 for 20 min secreted IL-2 at a rate of 1,200 ± 160 ng/106 cells per day. C57B1/6J mice immunized with irradiated, HSV-IL-2-transduced tumor cells produced in this way demonstrated specific tumor immunity by in vitro splenocyte tumoricidal activity and by in vivo protection against tumor challenge. Human hepatobiliary tumor specimens harvested at the time of operation, irradiated, and infected with HSV-IL-2 also produced nanogram quantities of IL-2/106 cells per 24 hr. These results indicate that the HSV amplicon vector is a good candidate vehicle for gene transfer in the production of autologous tumor vaccines. By allowing rapid gene transfer to freshly harvested tumor specimens, these vectors bypass the requirement for cell culture and make feasible reinfusion of genetically modified and irradiated autologous cells within hours of tumor harvest.

UR - http://www.scopus.com/inward/record.url?scp=0030450167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030450167&partnerID=8YFLogxK

M3 - Article

C2 - 8953312

AN - SCOPUS:0030450167

VL - 7

SP - 2217

EP - 2224

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 18

ER -